Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Gustoeson Jan 12, 2015 10:23pm
122 Views
Post# 23311968

RE:RE:RE:Desperation

RE:RE:RE:Desperation
Thera2014MJC73 wrote: Bencro-
now you're talking ph3.... I thought the mantra was fast track in early 2016!
Kiddo, we're talking 2018 or 2019 if it goes to ph3,
Even I'm not that pessimistic!

Get with the pump program! We gotta get the sp over $0.50.


He can't assume/take for granted that Phase2a (proof of concept) will automatically lead to fasttrack or breakthrough.

He's saying for stock risk for those of you's that are so concerned, you can't put money in the bank until phase iii success and final nda approval. So he's asking why are you here. Why not wait until 2015 is complete and whether fasttrack is granted or not if you are so worried?

Approx. timeline we have:
2015 is Phase 1/2a
....Phase 2a meetings.
if needed, 2016 would be Phase 2
if needed, 2018 would be Phase 3

Breakthrough could be granted after Phase 2a meetings... which would fall around end of this year/start of 2016 if everything goes according to plan. TLT has a strategy.

Reference
https://obroncology.com/obrgreen/print/FDAs-New-Breakthrough-Therapy-Designation
https://www.medicinenet.com/script/main/art.asp?articlekey=9877
https://www.virginia.edu/vpr/irb/HSR_docs/CLINICAL_TRIALS_Phases.pdf

Bullboard Posts